Your browser doesn't support javascript.
loading
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract Cancer.
Khadhouri, Sinan; Hramyka, Artsiom; Gallagher, Kevin; Light, Alexander; Ippoliti, Simona; Edison, Marie; Alexander, Cameron; Kulkarni, Meghana; Zimmermann, Eleanor; Nathan, Arjun; Orecchia, Luca; Banthia, Ravi; Piazza, Pietro; Mak, David; Pyrgidis, Nikolaos; Narayan, Prabhat; Abad Lopez, Pablo; Nawaz, Faisal; Tran, Trung-Thanh; Claps, Francesco; Hogan, Donnacha; Gomez Rivas, Juan; Alonso, Santiago; Chibuzo, Ijeoma; Gutierrez Hidalgo, Beatriz; Whitburn, Jessica; Teoh, Jeremy; Marcq, Gautier; Szostek, Alexandra; Bondad, Jasper; Sountoulides, Petros; Kelsey, Tom; Kasivisvanathan, Veeru.
Afiliação
  • Khadhouri S; School of Medicine, University of St Andrews, St Andrews, UK; British Urological Researchers in Surgical Training (BURST), London, UK. Electronic address: sinan.khadhouri@doctors.org.uk.
  • Hramyka A; School of Computer Science, University of St Andrews, St Andrews, UK.
  • Gallagher K; British Urological Researchers in Surgical Training (BURST), London, UK; Institute of Cancer and Genetics, University of Edinburgh, Edinburgh, UK; Division of Surgery and Interventional Science, University College London, London, UK.
  • Light A; British Urological Researchers in Surgical Training (BURST), London, UK; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Ippoliti S; British Urological Researchers in Surgical Training (BURST), London, UK; Department of Paediatric Surgery, Hull Royal Infirmary, Hull University Teaching Hospitals, Hull, UK.
  • Edison M; British Urological Researchers in Surgical Training (BURST), London, UK; Department of Urology, Chelsea and Westminster Hospital, London, UK.
  • Alexander C; British Urological Researchers in Surgical Training (BURST), London, UK; Luton and Dunstable University Hospital, Luton, UK.
  • Kulkarni M; British Urological Researchers in Surgical Training (BURST), London, UK; Department of Urology, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Zimmermann E; British Urological Researchers in Surgical Training (BURST), London, UK; Department of Urology, Southmead Hospital, Bristol, UK.
  • Nathan A; British Urological Researchers in Surgical Training (BURST), London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
  • Orecchia L; AOU Policlinico Tor Vergata University Hospital of Rome, Rome, Italy.
  • Banthia R; University Hospital Coventry Warwickshire, Coventry, UK.
  • Piazza P; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Mak D; Royal Wolverhampton Hospitals, Wolverhampton, UK.
  • Pyrgidis N; Department of Urology, University Hospital LMU, Munich, Germany.
  • Narayan P; Royal Berkshire Hospital, Reading, UK.
  • Abad Lopez P; Hospital Clinico San Carlos, Madrid, Spain.
  • Nawaz F; University Hospitals of Derby and Burton, Derby, UK.
  • Tran TT; Department of Surgery, Hanoi Medical University, Hanoi, Vietnam; Department of Urology, Hanoi Medical University Hospital, Hanoi, Vietnam.
  • Claps F; University of Trieste, Trieste, Italy.
  • Hogan D; Mercy University Hospital, Cork, Ireland.
  • Gomez Rivas J; Urologia-Hospital Clinico San Carlos, Madrid, Spain.
  • Alonso S; Urologia-Hospital Clinico San Carlos, Madrid, Spain.
  • Chibuzo I; Stepping Hill Hospital, Stockport, UK.
  • Gutierrez Hidalgo B; Clinico San Carlos Hospital, Madrid, Spain.
  • Whitburn J; Oxford University Hospitals, Oxford, UK.
  • Teoh J; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong.
  • Marcq G; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France; CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University Lille, Lille, France.
  • Szostek A; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
  • Bondad J; Southend University Hospital, Southend-on-Sea, Essex, UK.
  • Sountoulides P; Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Kelsey T; School of Computer Science, University of St Andrews, St Andrews, UK.
  • Kasivisvanathan V; British Urological Researchers in Surgical Training (BURST), London, UK; University College London, London, UK.
Eur Urol Focus ; 2024 Jun 20.
Article em En | MEDLINE | ID: mdl-38906722
ABSTRACT

BACKGROUND:

The IDENTIFY study developed a model to predict urinary tract cancer using patient characteristics from a large multicentre, international cohort of patients referred with haematuria. In addition to calculating an individual's cancer risk, it proposes thresholds to stratify them into very-low-risk (<1%), low-risk (1-<5%), intermediate-risk (5-<20%), and high-risk (≥20%) groups.

OBJECTIVE:

To externally validate the IDENTIFY haematuria risk calculator and compare traditional regression with machine learning algorithms. DESIGN, SETTING, AND

PARTICIPANTS:

Prospective data were collected on patients referred to secondary care with new haematuria. Data were collected for patient variables included in the IDENTIFY risk calculator, cancer outcome, and TNM staging. Machine learning methods were used to evaluate whether better models than those developed with traditional regression methods existed. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

The area under the receiver operating characteristic curve (AUC) for the detection of urinary tract cancer, calibration coefficient, calibration in the large (CITL), and Brier score were determined. RESULTS AND

LIMITATIONS:

There were 3582 patients in the validation cohort. The development and validation cohorts were well matched. The AUC of the IDENTIFY risk calculator on the validation cohort was 0.78. This improved to 0.80 on a subanalysis of urothelial cancer prevalent countries alone, with a calibration slope of 1.04, CITL of 0.24, and Brier score of 0.14. The best machine learning model was Random Forest, which achieved an AUC of 0.76 on the validation cohort. There were no cancers stratified to the very-low-risk group in the validation cohort. Most cancers were stratified to the intermediate- and high-risk groups, with more aggressive cancers in higher-risk groups.

CONCLUSIONS:

The IDENTIFY risk calculator performed well at predicting cancer in patients referred with haematuria on external validation. This tool can be used by urologists to better counsel patients on their cancer risks, to prioritise diagnostic resources on appropriate patients, and to avoid unnecessary invasive procedures in those with a very low risk of cancer. PATIENT

SUMMARY:

We previously developed a calculator that predicts patients' risk of cancer when they have blood in their urine, based on their personal characteristics. We have validated this risk calculator, by testing it on a separate group of patients to ensure that it works as expected. Most patients found to have cancer tended to be in the higher-risk groups and had more aggressive types of cancer with a higher risk. This tool can be used by clinicians to fast-track high-risk patients based on the calculator and investigate them more thoroughly.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article